Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2025 Jul:198:108378.
doi: 10.1016/j.maturitas.2025.108378. Epub 2025 May 2.

Menopause and hair loss in women: Exploring the hormonal transition

Affiliations
Free article
Review

Menopause and hair loss in women: Exploring the hormonal transition

Aditya K Gupta et al. Maturitas. 2025 Jul.
Free article

Abstract

Menopause, which is defined as the cessation of menstruation, may be preceded by hormonal fluctuations during the transition to menopause, up to 10 years prior. During this time, hormonal changes, including the relative increase in androgens and the cessation of ovarian estrogen production directly impacts the hair follicle, which is an estrogen-sensitive tissue. These hormonal fluctuations can lead to alterations in the hair shaft and hair cycle, including decreased density, decreased caliber, and changes in hair texture. Additionally, loss of estrogen after the onset of menopause may lead to sub-optimal metabolic and vascular functioning of the follicular unit. The overall decline in hair density, appearance and manageability can have significant emotional impact and affect overall mental health, with feelings of stress, anxiety, and diminished self-esteem. In addition to the physiologic changes that can occur in the hair follicle during menopause, certain hair disorders, including female-pattern hair loss, telogen effluvium, and frontal fibrosing alopecia, have been noted with higher frequency in post-menopausal women.

Keywords: Alopecia in menopause; Female-pattern hair loss (FPHL); Frontal fibrosing alopecia (FFA); Post-menopausal hair loss; Telogen effluvium.

PubMed Disclaimer

Conflict of interest statement

Declaration of competing interest AKG, VE, AM and TW have no competing interests to declare. PM reports research grants for conducting clinical trials from Amgen, Sun Pharmaceuticals, Eli Lilly, Incyte, and Pfizer; has served on the board of directors and medical advisory board for the American Hair Research Society, National Alopecia Areata Foundation, and Scarring Alopecia Foundation; and is a consultant for NeoGenesis.

LinkOut - more resources